Skip to main content
. Author manuscript; available in PMC: 2016 Jun 29.
Published in final edited form as: Aliment Pharmacol Ther. 2015 Oct 28;43(1):134–144. doi: 10.1111/apt.13440

Table 2.

Reasons for discontinuation of Entecavir

Reason for discontinuation Number %
Self discontinuation 48 44.4
Provider recommendation- reached therapeutic endpoint 25 23.1
Provider recommendation- suboptimal clinical response 11 10.2
Adverse events: 8 7.4
  Lactic acidosis 2
  GI, dermatologic, miscellaneous 6
Pregnancy related 6 5.6
Miscellaneous- lost to follow up 6 5.6
Suspected ETV resistance 4 3.7
Total 108